Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.
about
Current and emerging strategies for the prevention of graft-versus-host diseaseReduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignanciesAn intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies.A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignanciesA comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host diseaseExperience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying DiseasePeritransplant palifermin use and lymphocyte recovery after T-cell replete, matched related allogeneic hematopoietic cell transplantation.High proportions of regulatory T cells in PBSC grafts predict improved survival after allogeneic haematopoietic SCT.A comparative study of reduced dose alemtuzumab in matched unrelated donor and related donor reduced intensity transplants.Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantationPeripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT.Immune recovery after allogeneic hematopoietic stem cell transplantation: is it time to revisit how patients are monitored?Thinking out of the box--new approaches to controlling GVHD.Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: past, present and future.Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Recipient/donor HLA and CMV matching in recipients of T-cell-depleted unrelated donor haematopoietic cell transplants.Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation.Allogeneic Reduced-Intensity Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease: a Single-Center Prospective Trial.Outcomes of mismatched and unrelated donor hematopoietic stem cell transplantation in Fanconi anemia conditioned with chemotherapy only.Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation.Alemtuzumab in allogeneic hematopoetic stem cell transplantation.Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study.No indication of increased infection rates using low-dose alemtuzumab instead of anti-thymocyte globulin as graft-versus-host disease prophylaxis before allogeneic stem cell transplantation.Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party.Reduced platelet transfusions and earlier platelet engraftment using alemtuzumab-based conditioning regimen in allogeneic stem cell transplantation.Low-dose alemtuzumab for GvHD prevention followed by prophylactic donor lymphocyte infusions in high-risk leukemia.Role of αβ T Cell Depletion in Prevention of Graft versus Host Disease.Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: a British Society of Blood and Marrow Transplantation study.Haploidentical stem cell transplantation augmented by CD45RA negative lymphocytes provides rapid engraftment and excellent tolerability.Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemiaT cell depletion utilizing CD34+ stem cell selection and CD3+ addback from unrelated adult donors in paediatric allogeneic stem cell transplantation recipients
P2860
Q27016541-B69D5FFD-657D-4D3F-BF1D-CA09AD5D554FQ34075082-2876F246-7AF5-453E-AD88-4588862E0121Q34206291-4B732F21-5A2A-4F48-8035-D5C92E55B0CAQ35083281-1FA29A10-0DB4-4F24-9EAA-5E5227FBFF99Q35213027-540D4FB9-9E8D-400D-AC33-4F875F495106Q35285087-C732DAF1-9318-4442-906C-1150BB17939AQ35930604-610DB631-AEC3-43AE-8697-C695EB6FB9F0Q36156205-4130D713-F331-4B9B-9048-5B83A341244DQ36247091-C13B4E0E-478B-4C84-B50E-56B5B38F236EQ36442493-9FD41732-2949-4CC5-BF74-813EF82F9111Q36532550-6BEB2364-FA6B-4114-ABB5-30F30D81CB0CQ36891433-DA2A16B2-6D5D-4AA7-ACDD-061FCBE0F1BFQ37079011-53DD43B2-49AD-44B8-B1B5-80AF2B2BC031Q37211141-D6C8B8B7-458C-42C0-9F7D-A2349B8C821FQ38175862-A229999E-3882-478D-8E5C-7B557904B75CQ38742867-B2FFD13D-E483-49B0-8578-BCF9250E4D65Q38816505-F1F55566-015F-4D03-B276-8327B4ECD906Q39018399-17ADE18C-A14A-4788-8EBD-9F9B1AF7A892Q39036486-45C1ECAC-21A4-4CD2-A816-A7980BE25D7AQ39459351-D80F2090-9EC2-46EE-97FF-F238EF744F5BQ40116020-6FE82989-E234-46E6-B961-2CDE181BE0E4Q41344437-C92EFEC3-F1B0-4914-B58E-EEFE311ED1F6Q42030698-3243B0C9-14FE-4FC6-8AC9-F57729A53490Q42149544-9ACCA43D-145F-444A-9839-A0F02D400C68Q44399798-4ECF228E-28FB-4B36-9C68-4B723572F62EQ47572547-B1F24486-1F55-4D4B-A634-5B6BEF8FAB9CQ50042359-C816ABA0-98D9-4131-A19B-6DFF4A76C97EQ50268592-3A5FB614-CE0E-4BA2-9352-CCFE96770265Q51017254-514103CF-02CC-41E9-B814-6583EB1784B0Q52763837-328F4DF4-2F77-40D3-B0A5-AF39917C69DBQ52838715-A2C616BB-F49E-47F0-B4C9-4F1831A50B9DQ53652856-D6C7AA21-1173-457B-A0C3-C45405415C38Q56461161-1A70B208-4059-4F40-9FE3-F7C16E42B6DAQ58449860-ADBE5B3F-4C28-459E-9F10-113B6A2ADC33
P2860
Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Impact of in vivo alemtuzumab ...... HD, and immune reconstitution.
@en
Impact of in vivo alemtuzumab ...... HD, and immune reconstitution.
@nl
type
label
Impact of in vivo alemtuzumab ...... HD, and immune reconstitution.
@en
Impact of in vivo alemtuzumab ...... HD, and immune reconstitution.
@nl
prefLabel
Impact of in vivo alemtuzumab ...... HD, and immune reconstitution.
@en
Impact of in vivo alemtuzumab ...... HD, and immune reconstitution.
@nl
P2093
P1433
P1476
Impact of in vivo alemtuzumab ...... HD, and immune reconstitution.
@en
P2093
Adele Fielding
Adrian Bloor
Andrew Clark
Andrew Pettitt
Charles Crawley
Donald Milligan
Emma Morris
Geoff Hale
Guillermo Orti
John Snowden
P304
P356
10.1182/BLOOD-2010-05-286856
P407
P577
2010-06-29T00:00:00Z